Posted by Michael Wonder on 09 Feb 2022
Evolus receives acceptance of submission in Australia, a pivotal step in approval process for Nuceiva
8 February 2022 - Evolus today announced the acceptance of its submission to the Australian TGA for regulatory approval of Nuceiva (prabotulinumtoxinA), the first and only neurotoxin dedicated exclusively to aesthetics.
Evolus expects to receive full TGA regulatory approval of Nuceiva in 2023.
The product received U.S. FDA approval in February 2019 under the brand name Jeuveau. Nuceiva received marketing approval in Europe and the United Kingdom in October 2019 and was approved by Health Canada in August 2018.
